CrushSCI.com
51.4平均天数
34中位天数
3最短天数
236最长天数
3842025发文量

Paper Review Records

全部论文审稿周期

30 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

4 天

Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial

作者
Franco Locatelli; Michelle L. Schoettler; David Bueno‐Sánchez; Sonali Chaudhury; Jude Fry; Eric Bachman; Min Qin; Cynthia Carrillo‐Infante; Cory Williams; Aviva Krauss; Sarah Lawson; Yoshiyuki Takahashi; Hideki Sano; Daiichirou Hasegawa; Hyoung Jin Kang; Christopher C. Dvorak展开收起
作者单位
1. Department of Pediatric Hematology and Oncology Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital and Catholic University of the Sacred Heart Rome Italy; 2. Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta and Emory University School of Medicine Atlanta Georgia USA; 3. Pediatric Hematology and Oncology Department La Paz University Hospital Madrid Spain; 4. Stem Cell Transplantation and Cellular Therapies Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine Chicago Illinois USA; 5. Alexion, AstraZeneca Rare Disease Baar Switzerland; 6. Alexion, AstraZeneca Rare Disease Boston Massachusetts USA; 7. Department of Hematology—Oncology Schneider Children's Medical Center of Israel Petah Tikva Israel; 8. Department of Oncology and Hematology Birmingham Children's Hospital National Health Service Foundation Trust Birmingham UK; 9. Department of Pediatrics Nagoya University Graduate School of Medicine Nagoya Japan; 10. Department of Pediatric Oncology Fukushima Medical University Hospital Fukushima Japan; 11. Hyogo Prefectural Kobe Children's Hospital Kobe Japan; 12. Department of Pediatrics, Seoul National University College of Medicine Seoul National University Cancer Research Institute, Seoul National University Children's Hospital Seoul Republic of Korea; 13. Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation University of California San Francisco San Francisco California USA展开收起
PDF源文件 DOI 网页
18 天

Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?

作者
Hagop Kantarjian; Ayalew Tefferi展开收起
作者单位
1. Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA; 2. Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota USA展开收起
PDF源文件 DOI 网页
9 天

Is Bone Marrow Examination Still Required at Diagnosis of Typical Chronic‐Phase Chronic Myeloid Leukemia? Evidence From Paired Peripheral Blood and Bone Marrow Cytogenetics

作者
Mohammed Al Kurnas; Muluken Megiso; Ayalew Tefferi; Xi Zhang; Kebede H. Begna展开收起
作者单位
1. Department of Internal Medicine Mayo Clinic Rochester Minnesota USA; 2. Department of Internal Medicine Jefferson Einstein Philadelphia Hospital Philadelphia Pennsylvania USA; 3. Department of Internal Medicine, Division of Hematology Mayo Clinic Rochester Minnesota USA; 4. Department of Laboratory Medicine and Pathology, Division of Hematopathology Mayo Clinic Rochester Minnesota USA展开收起
PDF源文件 DOI 网页
46 天

Longitudinal Kidney Function Trajectories and Their Association With Hemoglobin and Transfusion Phenotype in Adults With β‐Thalassemia

作者
Barbara Gianesin; Rodolfo Russo; Giovanni Battista Ferrero; Filomena Longo; Susanna Barella; Raffaella Origa; Roberto Lisi; Roberta Sciortino; Annamaria Pasanisi; Ilaria Foggetti; Eugenia Mariani; Giovan Battista Ruffo; Valeria Maria Pinto; Gian Luca Forni展开收起
作者单位
1. FORANEMIA ETS Foundation Genoa Italy; 2. Clinica Nefrologica, Dialisi e Trapianto IRCCS Azienda Ospedaliera Metropolitana Policlinico Ospedale San Martino Genoa Italy; 3. SSD Microcitemie e Malattie Rare Ematologiche Ospedale San Luigi Gonzaga, Orbassano Torino Italy; 4. Day Hospital Della Talassemia e Delle Emoglobinopatie Azienda Ospedaliero Universitaria di Ferrara Ferrara Italy; 5. S.C. Centro Delle Microcitemie e Anemie Rare ARNAS G. Brotzu Cagliari Italy; 6. Department of Medical Sciences and Public Health University of Cagliari Cagliari Italy; 7. UOD Talassemia ARNAS Garibaldi Catania Italy; 8. Centro Microcitemia “A. Quarta” Ospedale “A. Perrino” Brindisi Italy; 9. Hematology Unit IRCCS Giannina Gaslini Genoa Italy; 10. UO Ematologia Ospedale Civico Palermo Italy; 11. Hematology and Cellular Therapy Unit IRCCS Azienda Ospedaliera Metropolitana Policlinico Ospedale San Martino Genoa Italy展开收起
PDF源文件 DOI 网页
83 天

Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure

作者
Atsushi Marumo; Arda Durmaz; Christopher Haddad; Aashray Mandala; Felipe de Almeida Sartori; Akram Abushamma; Serhan Unlu; Xiaorong Gu; Zachary Brady; Matteo D'Addona; Kartik Lakhotiya; Luca Guarnera; Masanori Yoshida; Monika M. Toma; Mark D. Orland; Carlos Bravo‐Perez; Carmelo Gurnari; Koichi Takahashi; Tomasz Skorski; Stephan Hutter; Torsten Haferlach; Marcin Wlodarski; Valeria Visconte; Jaroslaw P. Maciejewski展开收起
作者单位
1. Department of Translational Hematology and Oncology Research Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA; 2. Department of Hematology Graduate School of Medicine, Nippon Medical School Tokyo Japan; 3. Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi D'aragona” Salerno Italy; 4. Hematology, Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy; 5. Department of Pediatric Hematology and Oncology Research Research Institute, National Center for Child Health and Development Tokyo Japan; 6. Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine Philadelphia Pennsylvania USA; 7. Department of Hematology and Medical Oncology Hospital Universitario Morales Meseguer, University of Murcia, IMIB‐Pascual Parrilla, CIBERER – Instituto de Salud Carlos III Murcia Spain; 8. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA; 9. Department of Cancer and Cellular Biology Temple University Lewis Katz School of Medicine Philadelphia Pennsylvania USA; 10. Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center Philadelphia Pennsylvania USA; 11. MLL Munich Leukemia Laboratory Munich Germany; 12. St. Jude Children's Research Hospital, Department of Hematology Memphis USA展开收起
PDF源文件 DOI 网页
35 天

New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification

作者
Naseema Gangat; Paola Guglielmelli; Alessandro M. Vannucchi; Ayalew Tefferi展开收起
作者单位
1. Division of Hematology Mayo Clinic Rochester Minnesota USA; 2. Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliera Universitaria Careggi, University of Florence Florence Italy展开收起
PDF源文件 DOI 网页

FAQ

AMERICAN JOURNAL OF HEMATOLOGY审稿要多久?

截至2026-11-17,CrushSCI 收录了 AMERICAN JOURNAL OF HEMATOLOGY 的 30 篇完整审稿记录。最快一篇从收稿到录用用了 3 天(Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management,2026-04-01 收稿,2026-04-04 录用),最慢一篇用了 236 天;平均 51.4 天,中位数 34 天。最快这篇的日期间隔异常短,建议点开原文核对。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。